The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Chowdhury B, Luu AZ, Luu VZ, Kabir MG, Pan Y, Teoh H, Quan A, Sabongui S, Al-Omran M, Bhatt DL, Mazer CD, Connelly KA, Verma S, Hess DA.
Chowdhury B, et al. Among authors: kabir mg.
Biochem Biophys Res Commun. 2020 Mar 26;524(1):50-56. doi: 10.1016/j.bbrc.2020.01.015. Epub 2020 Jan 21.
Biochem Biophys Res Commun. 2020.
PMID: 31980166